VERV
Verve Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
VERV Profile
Verve Therapeutics, Inc.
A clinical-stage biotech company pioneering gene editing therapies for cardiovascular diseases
201 Brookline Avenue
, Suite 601
, Boston
, Massachusetts 02215
--
Verve Therapeutics, Inc., was incorporated as a Delaware corporation on March 9, 2018. The company is a gene drug company that has pioneered a new approach to treating cardiovascular disease, or CVD, transforming the treatment from chronic management to one-way gene editing drugs. The company believes that a single course of treatment can provide significant health benefits over a lifetime for patients with atherosclerotic cardiovascular disease or ASCVD or at risk of atherosclerotic cardiovascular disease.